mAbxience | What’s next? Meet us at...
On March 16th and 17th the International Congress On Clinical Trials In Oncology And Hemato-Oncology (ICTO) will celebrate its first edition in London. During this congress, mAbxience will present the poster “Biosimilars Clinical Trials Design and Execution: Challenges from Sponsor Perspective”. Laura Ullate, one of the clinical study coordinators at mAbxience, will defend the poster during the […]
With the occasion of Farmaforum (IV Forum Pharmaceutical, Biopharmaceutical and Laboratory Technology), which will take place in Madrid on 1st and 2nd of March, BioSim organises the roundtable “Science and evidence in biosimilars”. The event, moderated by Regina Múzquiz, Managing Director of BioSim, will have Luisa Amoedo, Director of the mAbxience plant in León, as one of […]
From February 27th to March 2nd the BioProcess International West congress will take place in San Francisco, with a wide variety of key sessions and workshops. In the frame of the technology workshops, mAbxience R&D Director, Cédric Bès, will lead a conference under the title “Outsourcing Biosimilars Process Development”, sponsored by GE Healthcare. Details When? 28th February, 11:50 […]
mAbxience, as a company specialising in biosimilars, will take part in one of the reference events in this sector, the World Biosimilar Congress Europe 2016, to be held on 14th and 15th November in Basel. The most important companies of the industry will attend this event as well as representatives of official organisms of the sector and universities. […]
On May 24th mAbxience will take part on the session Science to Business: Case Studies comprehending innovator and biosimilar developments. Susana Millán, mAbxience´s Medical & RA Director, will present a case study on the biosimilar developments carried out by the company in this sector event promoted by Azierta and Biosim.
Barcelona, Spain This meeting will demonstrate the unique scientific and technical skills set needed to navigate the challenges in the manufacture and development of biosimilar medicines while understanding the changing regulatory environment. Biosimilar Drug Development World Europe 2016